After setback, Sanofi, GSK take tweaked COVID-19 vaccine into phase 2 Daiichi Sankyo poaches Kite's research lead Takeshita from parent Gilead Otonomy fails phase 3, adding another twist to ear disease saga In Partnership: Commercialization in Canada: Navigating Complex Requirements to Drive Product Success Novellus becomes Fore Biotherapeutics as it completes pivot from diagnostics to precision oncology Genmab creates new CMO, head of experimental medicines role for Ahmadi Amping up the immune system's T cells to improve their cancer-killing prowess The 10 most-anticipated drug launches of 2021 Featured Story | By Nick Paul Taylor Sanofi and GlaxoSmithKline have begun a phase 2 clinical trial of a new version of their adjuvanted recombinant protein-based COVID-19 vaccine candidate. The study start comes around two months after weak clinical data forced the partners to rethink the antigen formulation. read more |
| |
|---|
|
Top Stories By Ben Adams As Daiichi Sankyo looks to cement its place as a major cancer R&D player, the Japanese Big Pharma is boosting its C-suite by nabbing a cell therapy veteran as its new global head of research and development. read more By Nick Paul Taylor A phase 3 clinical trial of Otonomy’s Otividex in inner ear condition Ménière's disease has missed its primary endpoint. The setback comes almost four years after the generation of mixed data from two earlier phase 3 studies persuaded Otonomy to roll the dice on another pivotal clinical trial. read more In Partnership With: AmerisourceBergen The Canadian pharmaceutical market, which is among the 10 largest worldwide, has long been viewed as a top-tier launch destination. read more By Amirah Al Idrus NovellusDx started out as a diagnostics company but has been making moves toward becoming a cancer therapeutics biotech in recent months. Now, it’s wrapping its transformation up with a new name and a new CEO: Fore Biotherapeutics and Usama Malik, a former Immunomedics executive who orchestrated the company’s $21 billion buyout by Gilead. read more By Ben Adams Hoping to boost indications for its blockbuster cancer med Darzalex and create a new line of pipeline meds, Genmab has promoted its head of oncology Tahamtan Ahmadi, M.D., Ph.D., to run its research. read more By Arlene Weintraub A team led by the Princess Margaret Cancer Centre in Toronto discovered that chemotherapy drugs known as DNA hypomethylating agents directly affected the anti-tumor response of a specific type of T cell in several tumor types, including melanoma and breast cancer. They believe their findings could inspire new immuno-oncology combination treatments. read more By Beth Snyder Bulik,Angus Liu Fierce Pharma rounds up the top 10 of who’s who in anticipated drug launches for 2021, ranked by Evaluate consensus sales estimates for global sales in 2026. read more Enrollment Showcase | Sponsored by: University of Florida College of Pharmacy Learn about the Top 5-Ranked UF College of Pharmacy’s online graduate programs in pharmaceutical outcomes & policy. Select from five specializations, including the new pharmaceutical value assessment & communication option. Over half of graduates progress to a new role within one year. Register now. |
| |
|---|
|
Resources Sponsored By: Oracle Health Sciences New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19. Sponsored By: Within3 We enable virtual work — offering over-time sessions where participants are more focused, insights are more diverse and business goals are met. Sponsored By: Medidata, a Dassault Systèmes company 8 parameters to optimize your “Path to Virtualization” across site- and patient-centric capabilities in this Sponsor Edition eBook. Sponsored By: LabVantage Solutions Uncover the real impact of “digital transformation” with practical advice to help you plan your own transformative journey to a harmonized digital ecosystem. Sponsored By: Acorn AI, a Medidata Company Acorn AI has developed a flexible and scalable Commercial Data Model that provides pharmaceutical companies with the data-driven insights required to respond to the industry’s ever-changing landscape. Download the whitepaper to learn how Acorn AI’s intuitive data model enables launch success and more. Sponsored By: Outer Edge Technology Criminals Are Actively Exploiting The CV-19 Pandemic To Gain Entry To Enterprise Networks. Don’t Let Your Company Become A Cybercrime Statistic -- Make These Cost-Effective IT Changes Now! Sponsored by: Cytiva It’s an exciting time to pioneer what could be a life-changing medicine. Clear the path to the clinic with pro tips and expert insights from industry leaders. Sponsored by: Cytiva A one-stop hub for Cytiva resources to support process development and manufacturing of your novel molecule Sponsored by: Catalent Autologous cell therapies have seen propelled growth since 2017, with the spotlight on the first FDA approval of a chimeric antigen receptor (CAR) T cell immunotherapy, Kymriah® (tisagenlecleucel), for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia. Sponsored by: Premier Research Browse the latest learnings and insights from our clinical development professionals. Sponsored by: Catalent Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase. Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. Sponsored by: Catalent In a BioPharma Dive industry survey, planning and forecasting were identified as top concerns for trial sponsors. In response to this need, the CSM team at Catalent has developed a methodology for identifying, evaluating, and proactively managing the inherent risks involved in clinical trial supply chain management. Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. Learn what it takes to get a drug developed and approved February 23-24, 2021 | 12 p.m. EST / 9 a.m. PST For non-scientists. Learn the science driving biopharma. February 25-26, 2021 | 9 a.m. EST / 6 a.m. PST Learn what it takes to get a drug developed and approved March 9-10, 2021 | 9 a.m. EST / 6 a.m. PST BD&L Summit for Life Sciences March 9–10, 2021 | Virtual Event Learn the science driving biopharma. Specific for the non-scientist. March 18-19, 2021 | 12 p.m. EST / 9 a.m. PST Learn what it takes to get a drug developed and approved April 13-14, 2021 | 12 p.m. EST / 9 a.m. PST
Learn the science driving biopharma. Specific for the non-scientist. April 20-21, 2021 | 12 p.m. EST / 9:00 a.m. PST Learn what it takes to get a drug developed and approved April 22-23, 2021 | 9:00 a.m. EST / 6 a.m. PST Learn the science driving biopharma. Specific for the non-scientist. May 6-7, 2021 | 9:00 a.m. EST / 6 a.m. PST Vaccines, cell and gene therapy, therapeutic antibodies and RNA drugs May 20-21, 2021 | 12 p.m. EST / 9 a.m. PST Learn what it takes to get a drug developed and approved June 2-3, 2021 | 9 a.m EST / 6 a.m.PST Vaccines, cell and gene therapy, antibodies, and RNA-based drugs June 10-11, 2021 | 9 a.m. EST / 6 a.m. PST Drug Development Boot Camp® 2021 Onsite and VIRTUAL in real time November 17-18, 2021 | Register now! Pre-Boot Camp preparation is now available. | 